Fast 3D MR Spectroscopic Imaging of Human Breast Cancer

人类乳腺癌的快速 3D MR 光谱成像

• 批准号: 7591135
• 负责人: QIUHONG HE
• 金额: $ 27.14万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-06-01 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7591135
• 关键词: Adopted; Animal Model; Antineoplastic Agents; Benign; Biochemical; Biological Markers; Biopsy; Breast; Breast Cancer Early Detection; Breast Cancer Treatment; Cancer Patient; Cancerous; Cells; Characteristics; Chemicals; Choline; Clinical; Clinical Protocols; Clinical effectiveness; Data; Detection; Development; Diagnosis; Diagnostic; Diagnostic Specificity; Effectiveness; Grant; Human; Human Volunteers; Image; Imaging Techniques; Investigation; Laboratories; Lipids; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of prostate; Mammary Gland Parenchyma; Maps; Measurement; Metabolic; Metabolic Marker; Metabolism; Methods; Pathway interactions; Patients; Penetration; Physiologic pulse; Problem Solving; Proliferating; Protons; Relaxation; Research Personnel; Resolution; Scanning; Sensitivity and Specificity; Signal Transduction; Slice; Spatial Distribution; Specificity; Staging; Techniques; Testing; Time; Tissues; Treatment Protocols; Unsaturated Fats; Water; base; brain research; breast cancer diagnosis; breast lesion; cancer diagnosis; clinical Diagnosis; imaging modality; improved; in vivo; iproplatin; malignant breast neoplasm; molecular marker; novel; outcome forecast; peroxidation; programs; quantum; research study; response; spectroscopic imaging; tool; tumor

DESCRIPTION (provided by applicant): Malignant tumor metabolism including lipid sysnthesis and peroxidation differs from normal breast tissue and benign tumors. Some of these biochemical changes can be detected by proton MR spectroscopic imaging (MRSI) using lactate, choline, and unsaturated lipid as molecular markers of breast cancer for clinical diagnosis and prognosis. The proton NMR detection of metabolites in breast tissue, however, has been challenging due to the intense lipid and water signals that block the observation of low concentration of metabolites in breast tissue. The recent advances in magnetic resonance spectroscopy permits the detection of elevated choline level in malignant breast tumors, reflecting the rapid phosphblipid synthesis and high metabolic activities of the proliferating cells. We have developed the Sel-MQC MRSI methods to observe lactate and unsaturated lipid changes in clinical breast cancer, which eliminate lipid and water signals in a single scan by multiple quantum filtering. In this grant period, we will develop novel fast Sel-MQC techniques to improve the temporal resolution of the Sel-MQC MRSI for clinical breast cancer diagnosis. The following specific aims will be achieved: (1) To improve clinical MR diagnostic specificity of human breast cancer using the novel Sel-MQC sequences for simultaneous mapping of choline, lactate, and unsaturated lipid signals; (2) To develop fast 3D MRSI methods and improve the temporal resolution for quantitative Sel-MQC mapping of lactate, choline, and unsaturated lipid -in breast tissues. Clinical protocols will be developed to quantitatively evaluate lactate and choline, and unsaturated lipid as molecular markers of breast caner using the Sel-MQC methods on 3T clinical MRI scanners. We will studyapproximately 30 patients/yr for those who are undergoing breast MRI imaging and subsequent biopsy. The MRSI spectral data will be compared with the pathological diagnosis to determine the potential of the technique. This project will demonstrate the clinical effectiveness of MRSI as a non-invasive method using biomolecular markers for early detection of breast cancer with potentially high diagnostic specificity and sensitivity. If successful, the proton MRSI will also provide a method to evaluate responses to the breast cancer treatment regimens, as well as diagnostic tool for other extracranial cancers.

描述（由申请人提供）： 恶性肿瘤代谢，包括脂质系统，过氧化与正常乳腺组织和良性肿瘤不同。这些生化变化中的某些变化可以通过使用乳酸，胆碱和不饱和脂质作为乳腺癌的分子标记来检测质子MR光谱成像（MRSI），用于临床诊断和预后。 然而，由于强烈的脂质和水信号阻止了乳腺组织中低浓度的代谢产物观察到乳腺组织中代谢物的质子NMR检测。 磁共振光谱法的最新进展允许检测恶性乳腺肿瘤中胆碱水平升高，反映了增殖细胞的快速磷脂合成和高代谢活性。我们已经开发了SEL-MQC MRSI方法，以观察临床乳腺癌的乳酸和不饱和脂质变化，从而通过多次量子过滤消除了单个扫描中的脂质和水信号。在此赠款期间，我们将开发新型的快速SEL-MQC技术，以改善用于临床乳腺癌诊断的SEL-MQC MRSI的时间分辨率。将实现以下具体目标：（1）使用新型的SEL-MQC序列来提高人类乳腺癌的临床MR诊断特异性，以同时绘制胆碱，乳酸和不饱和脂质信号； （2）开发快速的3D MRSI方法，并改善乳酸，胆碱和不饱和脂质 - 乳腺组织的定量SEL -MQC映射的时间分辨率。将使用3T临床MRI扫描仪上的SEL-MQC方法来定量评估乳酸和胆碱的临床方案，并不饱和脂质作为乳腺癌的分子标记。我们将为正在进行乳房MRI成像和随后的活检的患者学习30名患者/年。将将MRSI光谱数据与病理诊断进行比较，以确定该技术的潜力。该项目将使用生物分子标记物来早日检测具有潜在的诊断特异性和敏感性的乳腺癌，以证明MRSI作为一种非侵入性方法的临床有效性。如果成功，质子MRSI还将提供一种评估对乳腺癌治疗方案的反应的方法，以及其他颅外癌症的诊断工具。